Metabolic Rescue in Pluripotent Cells from Patients with Mtdna Disease

Hong Ma,Clifford D. L. Folmes,Jun Wu,Robert Morey,Sergio Mora-Castilla,Alejandro Ocampo,Li Ma,Joanna Poulton,Xinjian Wang,Riffat Ahmed,Eunju Kang,Yeonmi Lee,Tomonari Hayama,Ying Li,Crystal Van Dyken,Nuria Marti Gutierrez,Rebecca Tippner-Hedges,Amy Koski,Nargiz Mitalipov,Paula Amato,Don P. Wolf,Taosheng Huang,Andre Terzic,Louise C. Laurent,Juan Carlos Izpisua Belmonte,Shoukhrat Mitalipov
DOI: https://doi.org/10.1038/nature14546
IF: 64.8
2015-01-01
Nature
Abstract:Mutations in mitochondrial (mt)DNA are associated with severe disorders for which treatment is currently limited; this study shows that mtDNA mutations can be genetically corrected and normal metabolic function restored in cells derived from patients with mtDNA disease and reprogrammed to pluripotency through factor-mediated reprogramming or via a somatic cell nuclear transfer approach. Mutations in mitochondrial (mt)DNA are associated with severe disorders for which treatment is currently limited. This study demonstrates that mtDNA mutations can be genetically corrected and normal metabolic function restored in skin fibroblasts derived from patients with mtDNA disease using pluripotent stem cells derived by both factor-meditated reprogramming (iPS cells) and somatic cell nuclear transfer (SCNT) approaches. Mitochondria have a major role in energy production via oxidative phosphorylation1, which is dependent on the expression of critical genes encoded by mitochondrial (mt)DNA. Mutations in mtDNA can cause fatal or severely debilitating disorders with limited treatment options2. Clinical manifestations vary based on mutation type and heteroplasmy (that is, the relative levels of mutant and wild-type mtDNA within each cell)3,4. Here we generated genetically corrected pluripotent stem cells (PSCs) from patients with mtDNA disease. Multiple induced pluripotent stem (iPS) cell lines were derived from patients with common heteroplasmic mutations including 3243A>G, causing mitochondrial encephalomyopathy and stroke-like episodes (MELAS)5, and 8993T>G and 13513G>A, implicated in Leigh syndrome. Isogenic MELAS and Leigh syndrome iPS cell lines were generated containing exclusively wild-type or mutant mtDNA through spontaneous segregation of heteroplasmic mtDNA in proliferating fibroblasts. Furthermore, somatic cell nuclear transfer (SCNT) enabled replacement of mutant mtDNA from homoplasmic 8993T>G fibroblasts to generate corrected Leigh-NT1 PSCs. Although Leigh-NT1 PSCs contained donor oocyte wild-type mtDNA (human haplotype D4a) that differed from Leigh syndrome patient haplotype (F1a) at a total of 47 nucleotide sites, Leigh-NT1 cells displayed transcriptomic profiles similar to those in embryo-derived PSCs carrying wild-type mtDNA, indicative of normal nuclear-to-mitochondrial interactions. Moreover, genetically rescued patient PSCs displayed normal metabolic function compared to impaired oxygen consumption and ATP production observed in mutant cells. We conclude that both reprogramming approaches offer complementary strategies for derivation of PSCs containing exclusively wild-type mtDNA, through spontaneous segregation of heteroplasmic mtDNA in individual iPS cell lines or mitochondrial replacement by SCNT in homoplasmic mtDNA-based disease.
What problem does this paper attempt to address?